Roche Sees Access Programs As Key To Growth In China, Brazil: Emerging Market Earnings Roundup (Part 1)
This article was originally published in PharmAsia News
With biosimilars on the horizon, the Swiss pharma cites Herceptin and MabThera as key growth drivers in emerging markets.
You may also be interested in...
The Swiss pharma reported a positive start to the year with its first quarter earnings on April 11, underscoring the strength of its oncology products as it continues to work on lifecycle management.
Facing a slow roll-out of COVID-19 vaccines, China is implementing more promotional measures and increasing the pressure on the public to get inoculated. Vaccine diplomacy efforts meanwhile are facing challenges.
Amid a rising tide of sentiment against foreign consumer brands in China, observers say the impact could be far-reaching. But other factors may be more important than public opinion, and innovation will remain a key to success for health sector players.